EF Hutton Initiates Coverage On UroGen Pharma with Buy Rating, Announces Price Target of $25
Portfolio Pulse from Benzinga Newsdesk
EF Hutton has initiated coverage on UroGen Pharma with a Buy rating and set a price target of $25.
October 14, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EF Hutton has initiated coverage on UroGen Pharma with a Buy rating and a price target of $25, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $25 by EF Hutton suggests a positive sentiment towards UroGen Pharma's stock. This is likely to attract investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100